A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Project: Research project

Project Details

StatusActive
Effective start/end date2/11/22 → 2/10/27

Funding

  • ModernaTX, Inc ( Award # ): $8,700.00